AFFY  Affymax Inc.

Exchange

NASDAQ

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

2.29M

Current Price

$0.06
+0.000 (+0.000%)

Book Price

$-0.19
Overvalued by 418.51%
Financial Institution

Company Metrics

  • P/E 0.744
  • P/S 54.451
  • P/B 0.442
  • EPS 0.082
  • Dividend 0 / 0%
  • Avg. Vol. 18,705.00
  • Shares 37.54M
  • Market Cap. 2.29M

Company Description

Affymax, Inc., a biopharmaceutical company, engages in the development of drugs for the treatment of serious and life-threatening conditions. The company is developing Hematide, which is in Phase III clinical trials for the treatment of anemia associated with chronic renal failure. Hematide is a synthetic peptide-based erythropoiesis stimulating agent designed to stimulate production of red blood ... more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Affymax, Inc. Announces a Special Cash Distribution and the Appointment of a ...
Business Wire (press release) - Nov 26, 2014
CUPERTINO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (OTCQB: AFFY) today announced that its Board of Directors has declared a special cash distribution to shareholders in the amount of $0.05 per share.
Affymax Likely Worthless: Omontys Kills At Least 9x More People Than Epogen
Seeking Alpha - Aug 28, 2013
Affymax, Inc. (OTCPK:AFFY) is a shell company that owns potential future royalty and milestone payments associated with the recently recalled drug Omontys (peginesatide).
Affymax: Emerging Data Supports Conclusion Omontys Likely Dead
Seeking Alpha - Nov 12, 2013
After reviewing the summary adverse event report data highlighting a shocking number of deaths associated with Omontys, (discussed here), we followed-up with the FDA to request more information.
Delisting of Securities of Telestone Technologies Corp, Affymax, Inc., Exide ...
GlobeNewswire (press release) - Jul 18, 2013
Delisting of Securities of Telestone Technologies Corp, Affymax, Inc., Exide Technologies, Orchard Supply Hardware Stores Corporation, Spire Corporation and Shengkai Innovations, Inc. From The NASDAQ Stock Market ...
Affymax, Inc. (OTCMKTS:AFFY) Crashes After Losing Partner
HotStocked - Jun 17, 2014
To elaborate - some years ago, AFFY was one of the more promising biotech companies on the OTC. It had intellectual property, strong partners, funded its operations successfully, and even managed to deliver a product on the market.
The end for Affymax
Seeking Alpha - Jun 24, 2014
With no hope for a return to the market for Omontys, Affymax's (AFFY) BOD approves the liquidation and dissolution of the company, subject to shareholder approval.
Affymax Board Announces Decision to Dissolve the Company - Business Wire (press release)
Affymax Board Approves Dissolving Troubled Company - Genetic Engineering News
Affymax, Inc. (NASDAQ:AFFY) Stock Shoots Up
HotStocked - Aug 9, 2010
On the next day, investors unlocked the upward potential of AFFY stock. Additional impact on the stock rush had the company's announcement about some strategic plans of Affymax and Takeda to collaborate on the development and co-commercialization of ...
Affymax stock plunges 85 percent on drug recall
Reuters - Feb 25, 2013
Shares of Affymax Inc AFFY.O fell 85 percent after it said serious adverse reactions, including death, were reported among some of those using its sole commercial product, anemia drug Omontys.
Affymax and Takeda Announce a Nationwide Voluntary Recall of All Lots of ... - Business Wire (press release)
Affymax Adopts Tax Benefit Preservation Plan to Protect Net Operating Loss ...
Business Wire (press release) - Nov 26, 2014
CUPERTINO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (OTCQB: AFFY) announced today that its Board of Directors has adopted a Tax Benefit Preservation Plan, or Rights Plan, in an effort to preserve the value of its significant net operating loss ...
How to Protect Your Retirement Plans
Benzinga - Jun 26, 2013
Imagine some unfortunately soul who invested his entire $500,000 savings into Affymax (OTC: AFFY) on February 22. On February 25, he would have lost over $425,000 due to the firm's recall of its core product.